Parcourir par auteur "Lazreg, F."
Résultats 1-2 de 2
-
A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma
Morschhauser, Franck; Recher, C.; Milpied, N.; et al.Ann. Oncol., 11-07-2015, 23, 2687-2695Article dans une revue scientifique -
Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up
Colombat, P.; Brousse, N.; Salles, G.; et al.Annals of Oncology, 09-2012, 23 (9), 2380-2385Article dans une revue scientifique